Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2024-02-21 00:00:00 ET · period of report 2024-02-16 · accession 0000875320-24-000070 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-02-21 | 2024-02-16+ | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | F - Tax | $422.54 | -2,626 | 21.6K | -11% | -$1.11M |
| 2024-02-21 | 2024-02-20 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | S - Sale | $420.79 | -801 | 19.7K | -4% | -$337.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-20 | F | D | 1,125 | $420.58 | 20,511 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-20 | S | D | 801 | $420.79 | 19,710 | D | — | — | |
| 3 | Common | Common Stock | 2024-02-16 | F | D | 1,501 | $424.01 | 21,636 | D | — | — |